Tivic Health targets FDA approval for Entolimod within 18 months, highlights transformation into biopharma
Q4 2024 Management View CEO Jennifer Ernst highlighted significant advancements, including the acquisition of exclusive worldwide rights to the Phase III immunomodulatory drug candidate Entolimod, ...
Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth
Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...
360Dx7h
Accelerate Diagnostics Submits Wave Platform, Gram-Negative Test to FDA
The company also reported that its fourth quarter revenues dropped 7 percent from a year ago, while its full-year 2024 revenues declined 3 percent.
Zacks Investment Research on MSN10h
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...
Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance
Accelerate Diagnostics, Inc. (Nasdaq: AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE™ system and positive blood culture ...
Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent
Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer ...
Fierce Pharma13h
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
Medicare coverage for Lyme disease
Typically, healthcare professionals prescribe antibiotics, such as amoxicillin, doxycycline, and cefuroxime axetil, to treat the early stages of Lyme disease.
Medindia23h
Novartis receives third FDA approval for oral Fabhalta (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 ...